Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), INF280, 69120 Heidelberg, Germany.
Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center (DKFZ), INF581, 69120 Heidelberg, Germany.
Nucleic Acids Res. 2024 Jun 10;52(10):5698-5719. doi: 10.1093/nar/gkae233.
AT-rich interaction domain protein 1A (ARID1A), a SWI/SNF chromatin remodeling complex subunit, is frequently mutated across various cancer entities. Loss of ARID1A leads to DNA repair defects. Here, we show that ARID1A plays epigenetic roles to promote both DNA double-strand breaks (DSBs) repair pathways, non-homologous end-joining (NHEJ) and homologous recombination (HR). ARID1A is accumulated at DSBs after DNA damage and regulates chromatin loops formation by recruiting RAD21 and CTCF to DSBs. Simultaneously, ARID1A facilitates transcription silencing at DSBs in transcriptionally active chromatin by recruiting HDAC1 and RSF1 to control the distribution of activating histone marks, chromatin accessibility, and eviction of RNAPII. ARID1A depletion resulted in enhanced accumulation of micronuclei, activation of cGAS-STING pathway, and an increased expression of immunomodulatory cytokines upon ionizing radiation. Furthermore, low ARID1A expression in cancer patients receiving radiotherapy was associated with higher infiltration of several immune cells. The high mutation rate of ARID1A in various cancer types highlights its clinical relevance as a promising biomarker that correlates with the level of immune regulatory cytokines and estimates the levels of tumor-infiltrating immune cells, which can predict the response to the combination of radio- and immunotherapy.
富含 AT 序列结合蛋白 1A(ARID1A)是 SWI/SNF 染色质重塑复合物的亚基,在各种癌症实体中经常发生突变。ARID1A 的缺失导致 DNA 修复缺陷。在这里,我们表明 ARID1A 发挥表观遗传作用,促进 DNA 双链断裂 (DSB) 修复途径,非同源末端连接 (NHEJ) 和同源重组 (HR)。ARID1A 在 DNA 损伤后积累在 DSBs 处,并通过招募 RAD21 和 CTCF 到 DSBs 来调节染色质环形成。同时,ARID1A 通过招募 HDAC1 和 RSF1 来控制激活组蛋白标记物、染色质可及性和 RNA聚合酶 II 的逐出,促进转录活跃染色质中 DSBs 处的转录沉默。ARID1A 耗竭导致微核的积累增加、cGAS-STING 途径的激活以及电离辐射后免疫调节细胞因子的表达增加。此外,接受放疗的癌症患者中 ARID1A 表达水平较低与几种免疫细胞的浸润增加相关。ARID1A 在各种癌症类型中的高突变率突出了其作为有前途的生物标志物的临床相关性,与免疫调节细胞因子的水平相关,并估计肿瘤浸润免疫细胞的水平,这可以预测放射和免疫治疗联合治疗的反应。